Skip to content

2021 European Society Of Medical Oncology (ESMO) Virtual Congress

A Phase 1b Study of the Dual MDMX/MDM2 Inhibitor, ALRN-6924, for the Prevention of Chemotherapy-induced Myelosuppression

View Poster

A Phase 1 Study of the Dual MDMX/MDM2 Inhibitor, ALRN 6924, in Healthy Volunteers

View Poster

2021 International Society For Experimental Hematology (ISEH) 50th Annual Scientific Meeting

ALRN-6924 is a Dual MDMX/MDM2 Inhibitor and Can Protect the Bone Marrow of Cancer Patients Treated with Chemotherapy

View Poster

2020 EORTC-NCI-AACR Symposium On Molecular Targets And Cancer Therapeutics

Prevention of Chemotherapy-induced Myelosuppression in SCLC Patients Treated with the Dual MDMX/MDM2 Inhibitor ALRN-6924

View Poster

2019 AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics

The Investigational Peptide Drug ALRN-6924, a Dual Inhibitor of MDMX and MDM2, is an Effective Myelopreservation Agent

View Poster

Interested in partnering with Aileron?
Please contact us.